Massive Bio publishes landmark prospective study demonstrating AI-driven clinical trial matching at scale in 3,804 cancer ...
Taletrectinib is an oral, potent, central nervous system-active, selective, next-generation ROS1 inhibitor specifically designed for the treatment of patients with advanced ROS1+ NSCLC. Taletrectinib ...
NEW YORK, May 13, 2025--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced that new ...
Massive Bio, a cancer patient matchmaker, has been selected by the Precision Cancer Consortium to help identify potential candidates for clinical trials. The consortium, founded in 2022, is focused on ...
NEW YORK--(BUSINESS WIRE)--Massive Bio, Inc., a leader in providing simplified and affordable access to precision oncology to cancer patients treated at community-based oncology practices, announced ...
The materials will be made available in the Publications section of Nuvation Bio’s website after the presentation. About Taletrectinib Taletrectinib is an oral, potent, central nervous system-active, ...
Nuvation Bio Inc. (NYSE: NUVB), a global biopharmaceutical company tackling some of the greatest unmet needs in oncology, today announced that new data from a matching-adjusted indirect comparison ...
Taletrectinib is an oral, potent, central nervous system-active, selective, next-generation ROS1 inhibitor specifically designed for the treatment of patients with advanced ROS1+ NSCLC. Taletrectinib ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results